住院早产儿右美托咪定与阿片类药物的使用
该多中心观察性队列研究纳入2010至2020年美国383个Pediatrix医疗集团NICU中胎龄22周0天至36周6天的住院早产儿共395122例,描述右美托咪定使用模式并分析其与阿片类药物使用的关系。共有384例(0.1%)接受右美托咪定,这些婴儿出生更不成熟、出生体重更低、住院时间更长、阿片类药物暴露更多且机械通气天数更多。右美托咪定使用从2010年的0.003%增至2020年的0.185%(趋势P<.001),总体阿片类药物暴露从2010年的8.5%降至2020年的7.2%(趋势P<.001)。首次右美托咪定暴露的中位矫正胎龄为31(IQR 27-36)周、中位出生后日龄为3(IQR 1-35)天,中位使用持续时间为6(IQR 2-14)天。作者认为需进一步研究右美托咪定对早产及危重婴儿的短期和长期影响。
要点
- 2010至2020年间383个NICU共395122例早产儿中仅384例(0.1%)接受右美托咪定,使用者58.9%为男性。
- 右美托咪定使用率从2010年0.003%升至2020年0.185%(趋势P<.001),同期总体阿片类药物暴露从8.5%降至7.2%(趋势P<.001)。
- 接受右美托咪定的早产儿出生更不成熟、出生体重更低、住院更长、阿片暴露更多、机械通气天数更多。
- 首次右美托咪定暴露中位矫正胎龄31(IQR 27-36)周、中位出生后日龄3(IQR 1-35)天,中位使用持续时间6(IQR 2-14)天。
- 美国食品药品监督管理局(FDA)未批准右美托咪定用于早产儿,但过去十年超说明书使用增加50倍。
适用人群与场景
- 2010至2020年在美国383个Pediatrix医疗集团NICU出生的早产儿,胎龄22周0天至36周6天,共395122例。
- 接受右美托咪定者384例(占0.1%,58.9%为男性),其出生更不成熟、出生体重更低、住院时间更长、阿片类药物暴露更多、机械通气天数更多。
研究设计与关键结果
- 多中心观察性队列研究,纳入2010至2020年美国383个Pediatrix医疗集团NICU的395122例早产儿,中位胎龄34(IQR 32-35)周,中位出生体重2040(IQR 1606-2440)g。
- 右美托咪定使用率从2010年0.003%升至2020年0.185%(趋势P<.001);总体阿片类药物暴露从2010年8.5%降至2020年7.2%(趋势P<.001)。
- 首次右美托咪定暴露中位矫正胎龄31(IQR 27-36)周,中位出生后日龄3(IQR 1-35)天,中位使用持续时间6(IQR 2-14)天。
- 美国食品药品监督管理局(FDA)未批准右美托咪定用于早产儿,但过去十年超说明书使用增加50倍。
证据类型、等级与局限
- 证据类型:多中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐;作者认为需进一步研究以明确右美托咪定对早产及危重婴儿的短期和长期影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Dexmedetomidine, an α2-adrenergic agonist, is not approved by the Food and Drug Administration for use in premature infants. However, the off-label use of dexmedetomidine in premature infants has increased 50-fold in the past decade. Currently, there are no large studies characterizing dexmedetomidine use in US neonatal intensive care units (NICUs) or comparing the use of dexmedetomidine vs opioids in infants.
OBJECTIVES: To describe dexmedetomidine use patterns in the NICU and examine the association between dexmedetomidine and opioid use in premature infants.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter, observational cohort study was conducted from November 11, 2022, to April 4, 2023. Participants were inborn infants born between 22 weeks, 0 days, and 36 weeks, 6 days, of gestation at 1 of 383 Pediatrix Medical Group NICUs across the US between calendar years 2010 and 2020.
MAIN OUTCOME AND MEASURE: Exposure to medications of interest defined as total days of exposure, timing of use, and changes over time.
RESULTS: A total of 395 122 infants were included in the analysis. Median gestational age was 34 (IQR, 32-35) weeks, and median birth weight was 2040 (IQR, 1606-2440) g. There were 384 infants (0.1% of total; 58.9% male) who received dexmedetomidine. Infants who received dexmedetomidine were born more immature, had lower birth weight, longer length of hospitalization, more opioid exposure, and more days of mechanical ventilation. Dexmedetomidine use increased from 0.003% in 2010 to 0.185% in 2020 (P < .001 for trend), while overall opioid exposure decreased from 8.5% in 2010 to 7.2% in 2020 (P < .001 for trend). The median postmenstrual age at first dexmedetomidine exposure was 31 (IQR, 27-36) weeks, and the median postnatal age at first dexmedetomidine exposure was 3 (IQR, 1-35) days. The median duration of dexmedetomidine receipt was 6 (IQR, 2-14) days.
CONCLUSION AND RELEVANCE: The findings of this multicenter cohort study of premature infants suggest that dexmedetomidine use increased significantly between 2010 and 2020, while overall opioid exposure decreased. Future studies are required to further examine the short- and long-term effects of dexmedetomidine in premature and critically ill infants.
参考来源
- Curtis S, Kilpatrick R, Billimoria ZC, et al. Use of Dexmedetomidine and Opioids in Hospitalized Preterm Infants. JAMA Netw Open. 2023. PMID: 37921767. doi:10.1001/jamanetworkopen.2023.41033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。